Comparison of two molecular assays for detection and characterization of Aspergillus fumigatus triazole resistance and Cyp51A mutations in clinical isolates and primary clinical samples of immunocompromised patients

In hematological patients, the incidence of invasive aspergillosis (IA) caused by azole resistant As-pergillus fumigatus (ARAf) is rising. As the diagnosis of IA is rarely based on positive culture in this group of patients, molecular detection of resistance mutations directly from clinical samples...

Full description

Saved in:
Bibliographic Details
Main Authors: Postina, Patricia Amely Elisabeth (Author) , Boch, Tobias (Author) , Skladny, Julian (Author) , Miethke, Thomas (Author) , Merker, Natalia (Author) , Hofmann, Wolf-Karsten (Author) , Buchheidt, Dieter (Author) , Spiess, Birgit (Author)
Format: Article (Journal)
Language:English
Published: 27 March 2018
In: Frontiers in microbiology
Year: 2018, Volume: 9
ISSN:1664-302X
DOI:10.3389/fmicb.2018.00555
Online Access:Verlag, kostenfrei, Volltext: http://dx.doi.org/10.3389/fmicb.2018.00555
Verlag, kostenfrei, Volltext: https://www.frontiersin.org/articles/10.3389/fmicb.2018.00555/full
Get full text
Author Notes:Patricia Postina, Julian Skladny, Tobias Boch, Oliver A. Cornely, Axel Hamprecht, Peter-Michael Rath, Jörg Steinmann, Oliver Bader, Thomas Miethke, Anne Dietz, Natalia Merker, Wolf-Karsten Hofmann, Dieter Buchheidt and Birgit Spiess

MARC

LEADER 00000caa a2200000 c 4500
001 1572236388
003 DE-627
005 20210815110914.0
007 cr uuu---uuuuu
008 180423s2018 xx |||||o 00| ||eng c
024 7 |a 10.3389/fmicb.2018.00555  |2 doi 
035 |a (DE-627)1572236388 
035 |a (DE-576)502236388 
035 |a (DE-599)BSZ502236388 
035 |a (OCoLC)1263973914 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Postina, Patricia Amely Elisabeth  |d 1990-  |e VerfasserIn  |0 (DE-588)1080534164  |0 (DE-627)84477524X  |0 (DE-576)453598153  |4 aut 
245 1 0 |a Comparison of two molecular assays for detection and characterization of Aspergillus fumigatus triazole resistance and Cyp51A mutations in clinical isolates and primary clinical samples of immunocompromised patients  |c Patricia Postina, Julian Skladny, Tobias Boch, Oliver A. Cornely, Axel Hamprecht, Peter-Michael Rath, Jörg Steinmann, Oliver Bader, Thomas Miethke, Anne Dietz, Natalia Merker, Wolf-Karsten Hofmann, Dieter Buchheidt and Birgit Spiess 
264 1 |c 27 March 2018 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Gesehen am 23.04.2018 
520 |a In hematological patients, the incidence of invasive aspergillosis (IA) caused by azole resistant As-pergillus fumigatus (ARAf) is rising. As the diagnosis of IA is rarely based on positive culture in this group of patients, molecular detection of resistance mutations directly from clinical samples is crucial. In addition to the in-house azole resistance ARAf polymerase chain reaction (PCR) assays detecting the frequent mutation combinations TR34/L98H, TR46/Y121F/T289A and M220 in the Aspergillus fumigatus (A. fumigatus) Cyp51A gene by subsequent DNA sequence analysis, we investigated in parallel the commercially available AsperGenius® real time PCR system in detecting the Cyp51A alterations TR34/L98H and Y121F/T289A directly from 52 clinical samples (15 biopsies, 22 bronchoalveolar lavage (BAL), 15 cerebrospinal fluid (CSF) samples) and ARAf isolates (n=3) of im-munocompromised patients. We analyzed DNA aliquots and compared both methods concerning amplification and detection of Aspergillus DNA and Cyp51A alterations. As positive control for the feasibility of our novel Y121F and T289A PCR assays, we used two A. fumigatus isolates with the TR46/Y121F/T289A mutation combination isolated from hematological patients with known Cyp51A alterations and a lung biopsy sample of a patient with acute myeloid leukemia (AML). The rate of positive ARAf PCR results plus successful sequencing using the ARAf PCR assays was 61 % in biopsies, 29 % in CSF, 67 % in BAL samples and 100 % in isolates. In comparison the amount of positive PCRs using the AsperGenius® assays was 47 % in biopsies, 42 % in CSF, 59 % in BAL samples and 100 % in isolates. Altogether 17 Cyp51A alterations were detected using our ARAf PCRs plus DNA sequencing and therefrom 10 alterations also by the AsperGenius® system. The comparative evaluation of our data revealed that our conventional PCR assays are more sensitive in detecting ARAf in BAL and biopsy samples, whereby differences were not significant. The advantage of the AsperGenius® system is the time saving aspect. We consider non-culture based molecular detection of Aspergillus triazole resistance to be of high epidemiological and clinical relevance in patients with hematological malignancies. 
650 4 |a Clinical samples 
650 4 |a invasive aspergillosis 
650 4 |a Molecular assays 
650 4 |a PCR 
650 4 |a Triazole resistance 
700 1 |a Boch, Tobias  |d 1984-  |e VerfasserIn  |0 (DE-588)1052922015  |0 (DE-627)789313847  |0 (DE-576)40866732X  |4 aut 
700 1 |a Skladny, Julian  |d 1994-  |e VerfasserIn  |0 (DE-588)1214269427  |0 (DE-627)1725243326  |4 aut 
700 1 |a Miethke, Thomas  |d 1960-  |e VerfasserIn  |0 (DE-588)131537083  |0 (DE-627)707658012  |0 (DE-576)298571099  |4 aut 
700 1 |a Merker, Natalia  |d 1978-  |e VerfasserIn  |0 (DE-588)1080535055  |0 (DE-627)844777668  |0 (DE-576)453600182  |4 aut 
700 1 |a Hofmann, Wolf-Karsten  |d 1967-  |e VerfasserIn  |0 (DE-588)114154635  |0 (DE-627)691208751  |0 (DE-576)351568336  |4 aut 
700 1 |a Buchheidt, Dieter  |d 1955-  |e VerfasserIn  |0 (DE-588)1028287461  |0 (DE-627)730538621  |0 (DE-576)375787380  |4 aut 
700 1 |a Spiess, Birgit  |d 1972-  |e VerfasserIn  |0 (DE-588)1028287496  |0 (DE-627)730538699  |0 (DE-576)37578764X  |4 aut 
773 0 8 |i Enthalten in  |t Frontiers in microbiology  |d Lausanne : Frontiers Media, 2010  |g 9(2018) Artikel-Nummer 555, 9 Seiten  |h Online-Ressource  |w (DE-627)642889384  |w (DE-600)2587354-4  |w (DE-576)335527094  |x 1664-302X  |7 nnas  |a Comparison of two molecular assays for detection and characterization of Aspergillus fumigatus triazole resistance and Cyp51A mutations in clinical isolates and primary clinical samples of immunocompromised patients 
773 1 8 |g volume:9  |g year:2018  |a Comparison of two molecular assays for detection and characterization of Aspergillus fumigatus triazole resistance and Cyp51A mutations in clinical isolates and primary clinical samples of immunocompromised patients 
856 4 0 |u http://dx.doi.org/10.3389/fmicb.2018.00555  |x Verlag  |x Resolving-System  |z kostenfrei  |3 Volltext 
856 4 0 |u https://www.frontiersin.org/articles/10.3389/fmicb.2018.00555/full  |x Verlag  |z kostenfrei  |3 Volltext 
951 |a AR 
992 |a 20180423 
993 |a Article 
994 |a 2018 
998 |g 1028287496  |a Spiess, Birgit  |m 1028287496:Spiess, Birgit  |d 60000  |d 61200  |e 60000PS1028287496  |e 61200PS1028287496  |k 0/60000/  |k 1/60000/61200/  |p 14  |y j 
998 |g 1028287461  |a Buchheidt, Dieter  |m 1028287461:Buchheidt, Dieter  |d 60000  |d 61200  |e 60000PB1028287461  |e 61200PB1028287461  |k 0/60000/  |k 1/60000/61200/  |p 13 
998 |g 114154635  |a Hofmann, Wolf-Karsten  |m 114154635:Hofmann, Wolf-Karsten  |d 60000  |d 61200  |e 60000PH114154635  |e 61200PH114154635  |k 0/60000/  |k 1/60000/61200/  |p 12 
998 |g 1080535055  |a Merker, Natalia  |m 1080535055:Merker, Natalia  |d 60000  |d 61200  |e 60000PM1080535055  |e 61200PM1080535055  |k 0/60000/  |k 1/60000/61200/  |p 11 
998 |g 131537083  |a Miethke, Thomas  |m 131537083:Miethke, Thomas  |d 60000  |d 61200  |e 60000PM131537083  |e 61200PM131537083  |k 0/60000/  |k 1/60000/61200/  |p 9 
998 |g 1052922015  |a Boch, Tobias  |m 1052922015:Boch, Tobias  |d 60000  |d 61200  |e 60000PB1052922015  |e 61200PB1052922015  |k 0/60000/  |k 1/60000/61200/  |p 3 
998 |g 1214269427  |a Skladny, Julian  |m 1214269427:Skladny, Julian  |d 60000  |e 60000PS1214269427  |k 0/60000/  |p 2 
999 |a KXP-PPN1572236388  |e 3006753283 
BIB |a Y 
SER |a journal 
JSO |a {"title":[{"title_sort":"Comparison of two molecular assays for detection and characterization of Aspergillus fumigatus triazole resistance and Cyp51A mutations in clinical isolates and primary clinical samples of immunocompromised patients","title":"Comparison of two molecular assays for detection and characterization of Aspergillus fumigatus triazole resistance and Cyp51A mutations in clinical isolates and primary clinical samples of immunocompromised patients"}],"language":["eng"],"name":{"displayForm":["Patricia Postina, Julian Skladny, Tobias Boch, Oliver A. Cornely, Axel Hamprecht, Peter-Michael Rath, Jörg Steinmann, Oliver Bader, Thomas Miethke, Anne Dietz, Natalia Merker, Wolf-Karsten Hofmann, Dieter Buchheidt and Birgit Spiess"]},"origin":[{"dateIssuedKey":"2018","dateIssuedDisp":"27 March 2018"}],"recId":"1572236388","person":[{"role":"aut","family":"Postina","given":"Patricia Amely Elisabeth","display":"Postina, Patricia Amely Elisabeth"},{"display":"Boch, Tobias","given":"Tobias","family":"Boch","role":"aut"},{"given":"Julian","display":"Skladny, Julian","family":"Skladny","role":"aut"},{"role":"aut","given":"Thomas","display":"Miethke, Thomas","family":"Miethke"},{"role":"aut","given":"Natalia","display":"Merker, Natalia","family":"Merker"},{"role":"aut","display":"Hofmann, Wolf-Karsten","given":"Wolf-Karsten","family":"Hofmann"},{"role":"aut","display":"Buchheidt, Dieter","given":"Dieter","family":"Buchheidt"},{"role":"aut","family":"Spiess","display":"Spiess, Birgit","given":"Birgit"}],"note":["Gesehen am 23.04.2018"],"relHost":[{"title":[{"title_sort":"Frontiers in microbiology","title":"Frontiers in microbiology"}],"origin":[{"dateIssuedKey":"2010","publisherPlace":"Lausanne","publisher":"Frontiers Media","dateIssuedDisp":"2010-"}],"note":["Gesehen am 23.12.10"],"physDesc":[{"extent":"Online-Ressource"}],"id":{"eki":["642889384"],"issn":["1664-302X"],"zdb":["2587354-4"]},"part":{"text":"9(2018) Artikel-Nummer 555, 9 Seiten","volume":"9","year":"2018"},"language":["eng"],"disp":"Comparison of two molecular assays for detection and characterization of Aspergillus fumigatus triazole resistance and Cyp51A mutations in clinical isolates and primary clinical samples of immunocompromised patientsFrontiers in microbiology","recId":"642889384","pubHistory":["1.2010 -"],"type":{"bibl":"periodical","media":"Online-Ressource"}}],"id":{"eki":["1572236388"],"doi":["10.3389/fmicb.2018.00555"]},"type":{"media":"Online-Ressource","bibl":"article-journal"}} 
SRT |a POSTINAPATCOMPARISON2720